Preimplantation genetic diagnosis and screening are widely accepted for chromosomal abnormality identification to avoid transferring embryos with genetic defects. Massively parallel sequencing (MPS) is a rapidly developing approach for genome analysis with increasing application in clinical practice. The purpose of this study was to use MPS for identification of aneuploidies and unbalanced chromosomal rearrangements after blastocyst biopsy. Trophectoderm (TE) samples of 38 blastocysts from 16 in vitro fertilization cycles were subjected to analysis. Low-coverage whole genome sequencing was performed using the Illumina HiSeq2000 platform with a novel algorithm purposely created for chromosomal analysis. The efficiency of this MPS approach was estimated by comparing results obtained by an Affymetrix single-nucleotide polymorphism (SNP) array. Whole genome amplification (WGA) products of TE cells were detected by MPS, with an average of 0.073 depth and 5.5% coverage of the human genome. Twenty-six embryos (68.4%) were detected as euploid, while six embryos (15.8%) contained uniform aneuploidies. Four of these (10.5%) were with solely unbalanced chromosomal rearrangements, whereas the remaining two embryos (5.3%) showed both aneuploidies and unbalanced rearrangements.
INTRODUCTION
Chromosomal abnormalities are among the major reasons for fetal developmental defects, causing implantation failures, spontaneous abortions, or late anomalies, or necessitating artificial termination of pregnancy [1] . To reduce the incidence of those defects, preimplantation genetic diagnosis and screening (PGD/PGS) have been introduced to detect a suspected abnormality or select the embryos with the highest developmental potential. According to the European Society of Human Reproduction and Embryology (ESHRE) consortium, embryos of over 3000 Robertsonian translocation carriers and reciprocal translocation carriers had been subjected to PGD from 1997 to 2007 [2] . Advanced maternal age, repeated implantation failure, and repeated miscarriage are the main indications for PGS to detect numerical chromosome errors [3] .
After the first report of PGD for X-linked diseases in 1990 [4] , single-blastomere biopsy from precompaction-stage embryos following fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) have become the dominant techniques for embryo analysis [5] . However, these approaches are restricted to selected chromosomes, and the information obtained from a single cell is not always representative of the whole embryo. In contrast, comparative genomic hybridization (CGH) or its advanced form, arraybased CGH, provide more information by analyzing all chromosomes at one time [6] [7] [8] [9] . Moreover, with the introduction of single-nucleotide polymorphism (SNP) array technologies, magnificent detection accuracy and resolution has been achieved by providing information not only for the chromosomal number but also the subchromosomal alterations [10] . With the combination of trophectoderm (TE) cell biopsy, blastocyst vitrification, and SNP array for diagnosis, Schoolcraft et al. [11] reported a significant improvement of the clinical outcome of implantation and live birth rate. However, the throughput and cost of an SNP array or an array-based CGH may limit widespread application in clinical laboratories.
Another rapidly developing and promising technique for chromosomal examination is massively parallel sequencing (MPS). Since the completion of the Human Genome Project [12] , the rapid innovation and advancement of sequencing technologies has led to dramatic reduction of the cost and turnaround time, as well as an astonishing improvement in sequencing quality. Compared to traditional capillary electrophoresis sequencing, MPS, which obtains the sequence of over a million DNA fragments, provides a more cost-effective approach for genomic study. Several recent studies have demonstrated the value of MPS in clinical applications, such as noninvasive prenatal diagnosis for fetal aneuploidy through low-coverage whole genome sequencing of maternal plasma [13] and identification of causative mutation in patients with Mendelian disease [14] . Moreover, Navin et al. [15] applied the combination of whole genome amplification (WGA) with MPS to detect copy number variations (CNVs) in single cells from tumor tissues. Another two studies demonstrated the possibility of analyzing a whole genome at single-nucleotide level in single cells [16, 17] .
Encouraged by this progress in clinical applications of MPS, the purpose of our work was to explore the potential of MPS in analysis of blastocyst TE biopsy samples for detection of aneuploidy and unbalanced chromosomal rearrangements, and the performance of MPS was evaluated by comparing the results with those of the SNP array using the same samples.
MATERIALS AND METHODS

Study Design
In order to evaluate the accuracy of aneuploidy and unbalanced chromosomal rearrangement detection using an MPS-based approach, donated Day 5 or 6 blastocysts were biopsied to obtain TE cells. After WGA, PCR products were analyzed by both MPS and SNP array. The inconsistencies between MPS and SNP arrays were further validated by quantitative real-time PCR (qPCR).
Collection of Samples
Thirty-eight blastocysts from 16 couples were collected after assisted reproduction treatment procedures in the CITIC Xiangya Reproductive & Genetic Hospital, with an average maternal age of 28.9 yr. Twenty-nine embryos were from 14 couples with structural chromosomal abnormalities such as translocations, and nine embryos were from another two euploid couples. Karyotype data of parents with chromosomal abnormalities are listed in Table  1 . All samples were obtained with the approval of the Institutional Review Board of both BGI-Shenzhen and CITIC Xiangya Reproductive & Genetic Hospital. All couples have participated in this trial on an informed-choice basis and have signed a consent form about donation of their leftover blastocysts for the purposes of this experiment.
TE Cells Biopsy
All embryos were cultured in Quinn's Blastocyst Medium (Sage) to the blastocyst stage. A hole was created in the zona pellucida on Day 3. Hatching blastocysts with the trophectodermal layer partially protruding through the hole of the zona on Day 5 or 6 were biopsied. Three to eight herniating TE cells were aspirated into the lumen of a pipette with internal diameter of 30 lm and detached from the blastocyst by laser firing on the area of constriction. Samples were then washed three times in PBS and preserved in PCR tubes with 2 ll PBS at À808C.
WGA of Genomic DNA of TE Cells
WGA was performed using the WGA4 GenomePlex Single Cell Whole Genome Amplification Kit (WGA4; Sigma Aldrich Inc.) according to the manufacturer's instructions. Briefly, samples were incubated at 508C for 1 h and heated to 998C with Single Cell Lysis & Fragmentation Buffer, then universal oligonucleotide primers were used to amplify the DNA fragment with 25 cycles of PCR. The quality of the amplified DNA was tested on a 2% agarose gel.
Library Construction and DNA Sequencing
WGA product (1-2 lg) was used for library construction according to the guidelines of Illumina sample preparation (Illumina). After fragmentation, the sticky ends of the DNA fragments were polished with T4 DNA polymerase and Klenow polymerase, then A base tailing was performed using Klenow exo-(3 0 to 5 0 exo minus). Specific sequencing adaptors with a single T base overhang at the 3 0 end were ligated to the above products and enriched by 10 cycles of PCR with an eight-base barcode of primers. After measuring the concentration and insert size, libraries were processed for single-end 50 cycles high-throughput sequencing using an Illumina HiSeq2000 sequencer (Illumina).
Bioinformatics Analysis for Chromosomal Abnormality Detection
The initial 20-base sequence of read was omitted for the following analysis to avoid the effects of the common WGA adaptor sequence. The remaining 30-base sequences were aligned to Human reference genome (Hg18; NCBIBuild36, http://www.ncbi.nlm.nih.gov/genome/guide/human/) by SOAP2 [18] , allowing a maximum of two base pair mismatches. After alignment, an algorithm developed in BGI-Shenzhen was used for chromosomal abnormality analysis. This algorithm included GC correction for WGA-induced bias removal, a binary segmentation algorithm for locating CNV breakpoints, and dynamic threshold determination for final signal filtering. For sex determination, the coverage ratio of the whole genome was used to assess the copy ratio of the Y chromosome, with 0.35 as a threshold. To compare with the results from the SNP array, we filtered the signals larger than 16 Mb in MPS analysis. All results were visualized by digital karyotyping for better presentation [19] .
Samples with chromosomal abnormalities were further selected for data simulation to evaluate the sensitivity and specificity of aneuploidy and CNV detection with different data sizes. Effective data from each sample that could be aligned to the reference genome were used for simulation with each data size, obtaining files with similar data size to be analyzed for sensitivity/ specificity evaluation. The positive signals of simulation with size more than half of the region were determined as abnormal, and the positive abnormal signal detected by simulation that was the same as the initial sample result was determined as true positive. The sensitivity was calculated as the ratio of the instances of true positive with the number of simulations. The specificity was calculated as the ratio of true positive signals with total positive signals of the initial sample.
SNP Array Analysis
WGA products were also processed for the SNP array to analyze aneuploidy and unbalanced chromosomal rearrangement in 23 chromosomes (the Y chromosome was not included). The amplified individual embryonic DNA was hybridized to the Gene Chip Mapping Nsp I 262K microarray (Affymetrix Inc.). Approximately 260 000 SNP signal intensities for each test sample were compared computationally with averaged signals from 30 previously evaluated normal female reference samples (data not shown). Copy number analysis was performed by Gene Chip Genotyping Analysis Software (GTYPE; Affymetrix Inc.) with smoothing size at 16M to minimize the noise hybrid signals. As the SNP array is unable to detect the Y chromosome, Y chromosom-specific PCR was performed for sex determination.
Quantitative Real-Time PCR Validation
The inconsistent results between the MPS and the SNP array were further validated by qPCR. For each region, three loci primers were designed and triplicate PCR was performed using blastocyst WGA product in 20 ll reaction volume with TaqMan Gene Expression Master Mix (Life Technologies) on a 7900 HT sequence detection system, as recommended by the supplier.
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Blastocysts with euploid karyotype were used as controls. The standard delta delta threshold cycle (DDC t ) method of relative quantitation was applied to calculate the copy ratio [20] .
RESULTS
Data Production
An average of 9.3 million reads were obtained for each embryo by MPS, covering 5.6% 6 1.9% of the whole human genome, with an average of 0.073 sequencing depth; 80.4% 6 3.5% of reads were aligned to the reference sequence and 71.9% 6 3.6% of reads were uniquely mapped by SOAP2, with an average duplication rate of 6.9%. The GC content was 41.3% 6 0.6% in accordance with that of the Human reference genome. The average coverage for mitochondrial DNA was 97.9% 6 2.6%, with an average 16.33 sequencing depth, which was 233 times higher than the depth of the whole genome.
Identification of MPS-Based Aneuploidies and Unbalanced Chromosomal Rearrangements
Karyotypes of in vitro fertilization (IVF) patients were identified by G-banding karyotyping of peripheral blood. There were four blastocysts for which one of both derivative chromosomes of the IVF parent was transmitted, including BLS11, BLS15, BLS17, and BLS37 (Table 1) .
Twenty one male and 17 female embryos were identified according to the coverage ratio of chromosome Y. Combining the low-coverage whole genome sequencing with the algorithm for analysis, 68% (26/38) of embryos were found euploid. Thirty-two percent (12/38) of embryos contained chromosomal abnormalities, including 15.8% (6/38) with uniform aneuploidies, 10.5% (4/38) with solely unbalanced rearrangements, and 5.3% (2/38) with both aneuploidies and unbalanced rearrangements. In total, four monosomies and five trisomies were identified in chromosomes 1, 3, 7, 13, 14, and 21, respectively, and 14 events of unbalanced rearrangements were observed in chromosomes 1, 2, 3, 5, 6, 11, 13, 17, and 21, respectively (Table 1) . Using and MPS-based approach, 12 embryos were classified as containing at least one chromosomal error.
Comparison of MPS and SNP Array Results
The SNP array also detected 26 euploid blastocysts and 12 embryos with chromosomal abnormalities (Table 1 ). All 26 euploid embryos as well as six embryos with uniform aneuploidies were correctly identified both by the MPS and SNP arrays (Table 1) . Eighty-three percent (5/6) of embryos 
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with unbalanced chromosome abnormalities showed consistent testing results as well (Table 2) . MPS revealed þ11 (pter-q23.3), À11 (q23.3-qter), and þ22 (q11.21-qter) of BLS11 (Fig. 1) . However, this anomaly of duplication in 11 (q11!q23.3) and deletion in 11 (q23.3!qter) were not detected in the SNP array for this sample ( Table 2 ). The two incongruous segments and 22 (q11.21-qter) in BLS11 were validated by qPCR, where the copy ratio of 11 (pter-q23.3) and 22 (q11.21-qter) was identified as three by all three loci, indicating a duplication, and the copy ratio of 11 (q23.3-qter) was identified as one by all three loci, indicating a deletion. The failed detection for the imbalance and breakpoint above in the SNP array may due to the bias from WGA that affected the SNP array result, but was corrected by MPS during bioinformatics analysis.
There were some discrepancies in the size of imbalanced segments between MPS and the SNP array, which might be related to the density of the probes. For instance, in sample BLS15 (Fig. 2) , we identified a 14.0-Mb duplication in 21 (q22.12-qter) by sequencing ( Fig. 2A) , but a 21.1-Mb duplication in 21 (q21-qter) by the SNP array (Fig. 2B) . The duplication in chromosome 21 of BLS15 was validated by qPCR as true, which was most possible from the father with a karyotype of 46, XY, t(3;21)(q21;q22).
Results above demonstrated that both MPS and the SNP array can identify embryo aneuploidy with 100% consistency. For the embryos with unbalanced chromosomal rearrangements, an MPS-based approach provided higher accuracy in some regions. There are þ11 (pter-q23.3) and a þ22 (q11.21-qter) duplications detected as green regions, and a À11 (q23.3-qter) deletion detected as red regions. Both the imbalanced segments were validated by qPCR. B) SNP array result of BLS11. There is a þ11 (p15.4-p13) duplication and a þ22 (q12.3-qter) duplication detected as a shift of copy number in the region from 2 to 3 (gain). Failed detection for the breakpoint in q23.3 of chromosome 11 in the SNP array platform may be due to the bias from WGA that affected the result, but it can be corrected by MPS during bioinformatics analysis.
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MPS Simulation for Sensitivity/Specificity Evaluation of Chromosomal Abnormalities
In order to determine the effective data size for detection of different types of chromosomal abnormalities by MPS, we selected all the abnormal samples to estimate the sensitivity/ specificity of this MPS-based approach with various sequencing sizes. We randomly selected 3 million, 2 million, 1 million, 0.5 million, and 0.1 million reads, and the specificity and sensitivity of aneuploidy and CNV detection with those reads were analyzed and illustrated in Figure 3 . It was found that both the specificity and sensitivity of aneuploidy detection were 100% with all different sequencing sizes, demonstrating that using as few as 0.1 million sequencing data reads, theoretically all types of aneuploidy could be identified correctly. While for CNV (.16 M) detection, with 0.5 million sequencing data reads, the sensitivity and specificity could achieve 95% and 96%, respectively.
DISCUSSION
TE cell samples derived from a total of 38 blastocysts were examined by MPS, and results were compared with those obtained with and SNP array. For the first time, we explored the use of MPS in chromosomal abnormality testing of human embryos, and demonstrated that low-coverage sequencing combined with WGA and bioinformatics analysis can effectively detect aneuploidies and unbalanced chromosomal rearrangements in TE cells.
A major advantage of this MPS-based approach to detection of chromosomal abnormality is the high accuracy of the approach, because it can correct the WGA bias during data analysis. The WGA bias cannot be avoided during SNP array analysis and may affect the reliability of the array results. Moreover, this new approach could provide relatively higher resolution for chromosomal abnormality detection. For each test sample, around 10 million reads were obtained as tags using the MPS-based approach, whereas the maximum density for SNP arrays is five million using Illumina. Moreover, extremely high genome coverage (more than 95%) and depth (over 163) was also observed in mitochondrial DNA by MPS. Accordingly, the mitochondrial DNA can be evaluated in parallel, which may act as another marker for evaluation of embryo quality, with potential impact on developmental competence [21, 22] .
Besides the accuracy, the costs of reagents, turnaround time, and throughput are also important factors when new technologies are suggested for application in clinical practice. In this study, the whole MPS-based procedure required 7-10 days in total and required cryopreservation of blastocysts to postpone transfer to the subsequent cycles. However, with the introduction of vitrification, pregnancy rates obtained with cryopreserved blastocysts after minimal or no stimulation may exceed those with fresh embryos [23, 24] , and may also decrease the incidence of ectopic pregnancies [25] . Moreover, several studies indicated that the combined approach of biopsy at the blastocyst stage, comprehensive chromosome analysis, vitrification, and warming and transfer of a single normal embryo might dramatically improve the overall efficiency [9, 11, 26, 27] . On the other hand, the sustained technical improvement for the benchtop sequencing platforms, such as Ion Torrent and MiSeq, could generate modest sequencing data in just a few hours and may make fresh transfer possible in the near future. There is a À3 (q22-qter) deletion detected as a red region, and a þ21 (q22.12-qter) duplication detected as a green region. B) SNP array result of BLS15. There is a À3 (q22-qter) deletion detected as a shift of copy number in the region from 2 to 1 (loss), and a þ21 (q21-qter) duplication detected as a shift of copy number from 2 to 3 (gain) .   FIG. 3 . The MPS simulation for specificity/sensitivity evaluation of CNVs and aneuploidy with different data sizes.
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Regarding the costs, it take only about $41 to generate 1 Gb sequencing data using Illumina HiSeq 2000 with paired-end 100-bp sequencing strategy [28] , which makes the MPS-based test comparable with conventional approaches. In our study, we obtained around 10 million sequencing data reads for each test sample. However, the sensitivity/specificity evaluation by MPS simulation has demonstrated that a minimum 500 and 100 K effective data size is enough for detection of unbalanced rearrangements and aneuploidy, respectively, both with high sensitivity and specificity. Accordingly, the estimated reagent cost for chromosomal abnormality detection is less than $100. Further development of sequencing technology still has a huge potential to reduce the cost to or below that of conventional approaches. The high throughput is another notable advantage of this MPS-based approach. By using the Illumina HiSeq2000 platform, more than 160 embryos could be processed in parallel in a labor-saving manner.
This study demonstrated a promising application of MPS in PGD/PGS. Apart from the expected further improvement in efficiency and sensitivity of MPS, it can also be used for complex clinical abnormalities, such as mosaicism [29] . In the present study, TE biopsy was used to obtain samples for multiple cells [30] ; however, MPS may also be useful for analysis of biopsied blastomeres and polar bodies.
In summary, with the rapid development of sequencing technology and continuously decreasing cost and time of sequencing, it is foreseeable that MPS will play an increasingly significant role in clinical laboratories for human-assisted reproduction applications and studies. Our work was the first to demonstrate the possibilities of this application. Further studies with large sample sizes and in vivo outcomes are needed for comprehensive evaluation to outline the potential for routine clinical application.
